Nov 16, 2005 · Abstract. HuMax-CD4 (zanolimumab) is a fully human monoclonal IgG1k antibody, targeting the CD4 molecule on T-cells.
Nov 16, 2005 · HuMax-CD4 (zanolimumab) is a fully human monoclonal IgG1k antibody, targeting the CD4 molecule on T-cells. It exhibits cytotoxic and anti- ...
Nov 16, 2006 · Zanolimumab (previously referred to as HuMax-CD4) is a fully human monoclonal IgG1k antibody, targeting the CD4 molecule on T-cells. It exhibits ...
Missing: non- | Show results with:non-
HuMax-CD4 (zanolimumab) is a fully human monoclonal IgG1k antibody, targeting the CD4 molecule on T-cells. It exhibits cytotoxic and anti-proliferative ...
Jun 23, 2009 · Zanolimumab (HuMax-CD4®; Genmab, Copenhaven, Denmark) is a monoclonal human anti-CD4 antibody and specifically targets Thelper cells as well ...
Missing: ongoing peripheral type
Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma. Y.H Kim. Stanford Cancer Center ...
Missing: ongoing peripheral non-
Zanolimumab is a fully human monoclonal cytotoxic IgG1κ antibody, targeting the CD4 molecule on T-cells. The present open-labeled exploratory clinical trial ...
There were forty-two patients evaluable for response with an overall response rate of 54.8% observed. The median duration of remission was short at 4.3 months ...
People also ask
What is monoclonal antibodies in clinical diagnosis?
What was the first monoclonal antibody approved by FDA?
What have monoclonal antibodies been used in the treatment of?
Zanolimumab, a fuly human monoclonal antibody: Preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphoma (PTCL). Blood [48th Annu ...
Jan 14, 2011 · Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphoma. British Journal of Haematology ...
Missing: fully | Show results with:fully